BioSpace News Archive

Protagonist Therapeutics, Inc. today announced that a late-breaking abstract featuring blinded, randomized withdrawal data from the rusfertide (PTG-300) REVIVE Phase 2 study in polycythemia vera (PV) has been accepted for oral presentation at the European Hematology Association (EHA) 2023 Congress.

AccuStem Sciences, Inc., a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced the establishment of a joint clinical collaboration agreement with University Hospitals.

Zura Bio Limited, a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, announced the final closing of a private placement resulting in gross proceeds to Zura Bio of approximately $80 million.

Teleflex Incorporated (NYSE: TFX), a leading global provider of medical devices for critical care and surgery, today announced that the Arrow ® EZ-IO ® Needle is the first and only Intraosseous (IO) Needle to receive 510(k) clearance from the U.S. Food and Drug Administration (FDA) for MR Conditional labeling.

Merck announced that Caroline Litchfield, executive vice president and chief financial officer, and Dr. Dean Y. Li, executive vice president and president, Merck Research Laboratories, are scheduled to participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Monday, June 12, 2023, at 4:00 p.m. PDT / 7:00 p.m. EDT.

Vyluma, Inc. (“Vyluma”) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for its lead compound, NVK002 (low dose atropine 0.01%) as a potential treatment for myopia in children.

Algernon Pharmaceuticals Inc. is pleased to announce that it will present its Phase 2a Ifenprodil cough data at the 9 th American Cough Conference (ACC) being held June 9-10, 2023 in Reston, Virginia.

MedSec, a leading medical device security services firm, announced the formation of its Technical Advisory Board.

Akeso, Inc. (9926.HK) (“Akeso”) released two-year updated data from a Phase Ib/II clinical study of cadonilimab – a first-in-class PD-1/CTLA-4 bispecific antibody developed by Akeso – in combination with chemotherapy as first-line therapy for advanced gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

BPGbio, Inc today announced that patients have been initially dosed in its Phase 2 trial for BPM 31510 for Glioblastoma Multiforme (GBM), a fast-growing and aggressive form of brain cancer.